Improved survival and marrow engraftment of mice transplanted with bone marrow of GM-CSF-treated donors.
Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) administered to bone marrow (BM) transplant recipients is associated with earlier recovery. We have investigated the possibility of stimulating normal donor mice in vivo with GM-CSF. Donor balb/c mice were injected i.p. with GM-CSF (5000 u) or saline. Seventy-two hours later 5 x 10(5)BM cells from either GM-CSF-treated or control donors were infused into lethally irradiated (850 R) recipients. In the recipients of BM from GM-CSF-treated donors, significantly higher CFU-S and significantly higher survival rate (57% [n = 65]; vs. 30% [n = 63]; p < 0.05) were noted. Donor mice of the GM-CSF group did not differ in bone-marrow cellularity and composition from their controls. However, recipients of BM from GM-CSF-treated mice had higher blood counts of haemoglobin, leukocytes and platelets compared to controls. These data demonstrate that pretreatment of BM donors with GM-CSF may be of benefit in improving survival and marrow engraftment in mice.
Ballin
A
A
Department of Haematology, Sackler School of Medicine, Tel Aviv, Israel.
Sagi
O
O
Schiby
G
G
Meytes
D
D
D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D003114:Colony-Forming Units Assay; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006454:Hemoglobins / Q000378:metabolism; D007958:Leukocyte Count / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D010976:Platelet Count / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology; D013154:Spleen / Q000187:drug effects / Q000502:physiology; D014185:Transplantation, Isogeneic
D006454:Hemoglobins; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor